Why Is Neuromuscular-Focused Dyne Therapeutics Stock Trading Lower On Friday?
Dyne Therapeutics' DYNE-101 shows promising Phase 1/2 results for myotonic dystrophy type 1, with plans for Accelerated ...
Dyne Therapeutics reports clinical data from its myotonic dystrophy type 1 treatment
Dyne Therapeutics (NASDAQ:DYN) reported clinical data from its ongoing Phase 1/2 trial of DYNE-101 in patients with myotonic dystrophy type 1. Shares down about 22% in early trade. DYNE-101 continued ...
Dyne Therapeutics Reports Positive Data From ACHIEVE Study Of DYNE-101 In Myotonic Dystrophy Type 1
(RTTNews) - Dyne Therapeutics, Inc. (DYN) Friday announced encouraging data from its ongoing Phase 1/2 ACHIEVE trial of DYNE-101 in patients with myotonic dystrophy type 1 (DM1). Myotonic dystrophy ...
BBC News' Clive Myrie battling condition that affects millions of Brits
BBC News presenter Clive Myrie sparked a flurry of concerned messages on social media on Monday night after he appeared on ...